Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines

Core Insights - Atossa Therapeutics supports new USPSTF guidelines recommending breast cancer screening for women starting at age 40, addressing rising breast cancer rates and disparities in diagnosis and mortality [1][2][4] Group 1: Guidelines and Impact - The updated guidelines suggest biennial mammography screening for women aged 40 to 74, responding to increased breast cancer rates among younger women and racial disparities [2] - The guidelines are set to take effect ahead of a September 2024 FDA deadline for mammogram facilities to provide detailed breast density information, which is a significant risk factor for breast cancer [2] Group 2: Company Initiatives - Atossa is evaluating its lead asset, (Z)-endoxifen, in five Phase 2 clinical trials, including a study focused on reducing mammographic breast density in premenopausal women [3][6] - The company emphasizes the importance of developing therapies to prevent breast cancer, noting that women with dense breast tissue are five times more likely to develop the disease [4] Group 3: Product Details - (Z)-endoxifen is a potent Selective Estrogen Receptor Modulator (SERM) that not only inhibits estrogen receptors but also degrades them, showing efficacy in patients resistant to other hormonal treatments [5] - Atossa is developing an oral formulation of (Z)-endoxifen that bypasses liver metabolism and stomach acidity, demonstrating good tolerance in early studies [6] Group 4: Company Overview - Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on innovative oncology medicines, particularly in breast cancer prevention and treatment [7]